ACPP PROTOCOL (ANTICIPATED CIRCUIT OF ANTICANCER INTRAVENOUS CHEMOTHERAPIES PRESCRIPTION AND PREPARATION IN A DAY HOSPITAL): OBSERVATIONAL STUDY ASSESSING THE IMPACT OF THE NEW WORKFLOW FOR HOSPITAL PHARMACY
PP-006
GALENIC PROPERTIES OF PLASMA RICH IN GROWTH FACTORS EYE DROPS
PP-005
IMPROVING SAFE PREPARATION OF INJECTABLE MEDICINES: THE EFFECTS OF INTRODUCING A SPORICIDAL AGENT
PP-004
CHEMICAL CONTAMINATIONS: UNDERSTAND TO PREVENT
PP-001
HYPROMELLOSE PROLONGS THE DISSOLUTION OF KETAMINE OUT OF GELATINE CAPSULES
PP-031
HAZARDOUS DRUGS: ANALYSIS OF CONSISTENCY WITH NEW RECOMMENDATIONS
PP-029
STABILITY OF FROZEN 1% VORICONAZOLE EYE DROPS IN GLASS AND IN INNOVATIVE CONTAINERS
PP-003
STABILITY STUDY OF BORTEZOMIB (VELCADE) WITH LIMIT TEST FOR ALL DEGRADATION PRODUCTS
PP-043
PROPRANOLOL 2 MG/ML AS SYRUP FOR SKIN ANGIOMAS. CLINICAL EVALUATION OF AN OFF-LABEL PREPARATION
PP-024
EVALUATION OF LONG TERM BIOLOGICAL ACTIVITY OF PEGASPARGASE (ONCASPAR) AFTER DILUTION IN NACL 0.9%
PP-001
CONTAMINATION WITH CYTOTOXIC DRUGS IN THE WORKPLACE ESOP PILOT STUDY
PP-039
DOUBLE CHECKING MANIPULATIONS FOR COMPLEX AND/OR HIGH RISK PREPARATIONS
PP-028
ARE COMMERCIAL MULTI-DOSE FORMULATIONS THE BEST SOLUTION? A SPECTROSCOPIC QUALITY STUDY OF CYCLOPHOSPHAMIDE
PP-046
ELABORATION OF A 10% SODIUM THIOSULFATE W/O TOPICAL CREAM FOR THE TREATMENT OF CALCINOSIS CUTIS IN TWO PREMATURE NEONATES
PP-045
EVALUATION OF COMPOUNDING QUALITY OF INTRAVENOUS ADMIXTURES
